

Supplementary table 1: Adjuvant treatment

Adjuvant Treatment	No (%)
ALL	137 (100%)
Chemotherapy	
Fluoropyrimidine ^a	39 (28%)
Fluoropyrimidine/platinum ^b	67 (49%)
Fluoropyrimidine/irinotecan	1 (1%)
Other 5Fu combinations ^c	8 (6%)
Gemcitabine	1 (1%)
Unknown	3 (2%)
Chemoradiation	
Fluoropyrimidine	4 (3%)
Chemotherapy +Chemoradiation	
Fluoropyrimidine/platinum ^d +Fluoropyrimidine XRT	9 (7%)
Fluoropyrimidine +Fluoropyrimidine XRT	2 (1%)
Fluoropyrimidine/Irinotecan +Fluoropyrimidine XRT	1 (1%)
Gemcitabine +Fluoropyrimidine XRT	2 (1%)

^a Fluoropyrimidine: 5FU or capecitabine

^b Platinum: oxaliplatin (65), cisplatin (1), carboplatin (1)

^c Other 5FU combinations: +Levamisole (3); +MMC (2); +IFN (1); +Etoposide/ Cisplatin (1); +MMC/Doxorubicin

^d Platinum: oxaliplatin (8), cisplatin (1)

Supplementary table 2: Neoadjuvant treatment

Neoadjuvant Therapy^d	No (%)
ALL	22 (100%)
Chemotherapy	
Fluoropyrimidine ^a /platinum ^b	5 (23%)
Other 5FU combinations (ECF)	1 (4%)
Gemcitabine/Paclitaxel	1 (4%)
Chemoradiation	
Fluoropyrimidine XRT	9 (41%)
Fluoropyrimidine/platinum ^c XRT	1 (4%)
Chemotherapy +Chemoradiation	
Fluoropyrimidine/platinum ^b +Fluoropyrimidine XRT	5 (23%)
Neoadjuvant treatment only	14 (63%)
Neoadjuvant treatment +Adjuvant chemotherapy	6 (27%)
Neoadjuvant treatment +Adjuvant chemoradiation	2 (10%)

^a Fluoropyrimidine: 5FU or Capecitabine

^b Platinum: Oxaliplatin

^c Platinum: Cisplatin

Supplementary table 3: Univariate and multivariate logistic regression for loco-regional recurrence (LR), and distant metastatic recurrence (DR)

		Loco-regional recurrence (LR) ¹				Distant metastatic recurrence (DR) ¹			
		Univariate Logistic Regression		Multivariate Logistic Regression		Univariate Logistic Regression		Multivariate Logistic Regression	
Category	Predictor	OR (95% CI for OR)	P- value	OR (95% CI for OR)	P- value	OR (95% CI for OR)	P- value	OR (95% CI for OR)	P- value
Age	≥ 58	1		1		1		1	
	< 58	0.49 (0.23-1.05)	0.07	0.41 (0.18-0.92)	0.03	2.54 (0.92-7.04)	0.08	2.98 (0.998-8.88)	0.05
Gender	Male					1			
	Female	0.73 (0.33-1.59)	0.43			1.84 (0.63-5.41)	0.27		
Race	White	1		1		1			
	Others ²	0.21 (0.05-0.94)	0.04	0.17 (0.04-0.79)	0.02	21755713.48 (0-Inf)	0.99		
Primary Tumor Location	Duodenum	1				1			
	Jejunum	1.40 (0.59-3.33)	0.45			0.4 (0.13-1.21)	0.10		
	Ileum	1.11 (0.43-2.87)	0.83			0.81 (0.21-3.10)	0.76		
MSI Status	dMMR	1				1			
	pMMR	0.12 (0.03-0.5)	0.004			5.71 (1.42-22.98)	0.01		
IBD	No	1				1			
	Yes	2.29 (0.79-6.59)	0.12			0.67 (0.17-2.58)	0.56		
Pathologic Stage	Stage 1-2	1				1			
	Stage 3	0.65 (0.31-1.37)	0.26			1.96 (0.73-5.21)	0.18		
T stage	T1/T2	1				1			
	T3	0.28 (0.06-1.25)	0.10			1.16 (0.13-10.63)	0.90		
	T4	0.37 (0.08-1.64)	0.19			0.76 (0.08-6.8)	0.80		
Margin status	R0	1				1			
	R1	0 (0-Inf)	0.99			7658066.22 (0-Inf)	0.99		
Histologic Grade	Grade 1-2	1				1			
	Grade 3	0.52 (0.23-1.17)	0.11			1.73 (0.61-4.94)	0.31		

Perineural invasion	No	1		1		1			
	Yes	3.35 (1.5-7.49)	0.004	3.58 (1.52-8.42)	0.004	0.68 (0.23-1.95)	0.47		
Lympho-vascular invasion	No	1				1			
	Yes	2.39 (1.11-5.13)	0.03			0.74 (0.28-1.94)	0.55		
Perioperative treatment	No perioperative treatment	1				1			
	Adjuvant	1.87 (0.79-4.43)	0.16			0.33 (0.09-1.22)	0.09		
	Neoadjuvant (+/-Adjuvant)	1.03 (0.19-5.66)	0.97			0.63 (0.06-6.73)	0.70		
Radiation therapy	No	1				1			
	Yes	1.01 (0.32-3.21)	0.99			0.76 (0.19-3.06)	0.70		

¹Total number of relapsed patients is 145

²Others= Black, Hispanic, and other races.